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Compensatory anabolic signaling 
in the sarcopenia of experimental 
chronic arthritis
Robert D. Little1,2, Iván Prieto-Potin2,3, Sandra Pérez-Baos2, Amanda Villalvilla  2, Paula 
Gratal2, Flavia Cicuttini1, Raquel Largo  2,3 & Gabriel Herrero-Beaumont2,3
Inflammatory activity in rheumatoid arthritis may alter the regulation of muscle mass leading to a 
secondary sarcopenia, commonly termed rheumatoid cachexia (RC). We characterized alterations 
to muscle structure and various pro-inflammatory, catabolic and regenerative markers in an animal 
model of RC. Antigen induced arthritis (AiA) was performed in 20 male adult rabbits. AiA animals 
exhibited significantly less weight gain, a markedly elevated serum C-reactive protein (CRP), lighter 
muscles with shorter cross-sectional diameter and increased myonuclei when compared to controls. 
Atrogin-1 and MuRF-1 were up-regulated alongside an increase in IL-1β, active NF-κB and a higher ratio 
of phosphorylated to inactive p38 MAPK. CCL-2 and TNF levels were reduced and IL-6 was unchanged 
between groups. We observed decreased pSTAT3, unchanged pSTAT1 and Myf5, but increased Pax7, 
MyoD and myogenin. AiA rabbits had a reduction in myostatin from gastrocnemii and synovium with 
a congruent decrease in serum myostatin compared to controls. Chronic arthritis induced an RC-like 
secondary sarcopenia with increased muscle protein breakdown. Elevated IL-1β may trigger proteolysis 
via elevated NF-κB and p38 MAPK signaling with a compensatory anabolic response suggested by 
myonuclear expansion, increased Pax7, MyoD and myogenin, reduced pSTAT3 as well as reduced 
serum, synovial and muscular myostatin.
Primary sarcopenia is a phenomenon of age-related loss of muscle mass and function affecting up to 30% of older 
adults1. Muscle loss in primary sarcopenia appears to be driven primarily by anabolic resistance. In contrast, 
secondary sarcopenia, such as the inflammatory muscle wasting of cancer, cardiac, and rheumatoid cachexia, 
appears to be driven by primarily catabolic processes. Additional pathways of muscle loss are activated by ano-
rexia, asthenia and inactivity associated with chronic systemic inflammation2.
Rheumatoid cachexia (RC), the condition of reduced skeletal muscle mass with either stable or increased fat 
mass, affects between 11% and 26% of rheumatoid arthritis (RA) patients worldwide3, 4. The sarcopenia of RC has 
been linked to the increased risk of osteoporosis, metabolic syndrome and cardiovascular disease observed in 
RA5, 6. Muscle loss in RA has also been associated with weakness, imbalance and a reduced quality of life, inde-
pendent of inflammatory severity and duration7.
Muscle homeostasis is maintained via a precise equilibrium between anabolic and catabolic processes. 
While poorly understood, inflammatory-mediated catabolism appears to be the major pathogenic factor in RC. 
Surrogate systemic markers of inflammation shown to correlate with altered body composition, including eryth-
rocyte sedimentation rate (ESR)8, C-reactive protein (CRP)9, tumor necrosis factor alpha (TNF)10 and inter-
leukin (IL)-611. A range of anti- and pro-inflammatory cytokines are now known to be secreted from skeletal 
muscle12. Indeed, increased muscle-derived TNF has been demonstrated in previous experimental models of 
RC13. However, muscle-derived IL-1β, IL-6 and chemokine ligand 2 (CCL-2) under arthritic conditions have 
not been previously quantified. TNF, IL-6 and IL-1β activate the ubiquitin-proteasome system (UPS), a common 
proteolytic pathway14. The UPS can be activated via Nuclear Factor-kappa B (NF-κB) and p38 Mitogen-Activated 
Protein Kinases (MAPK) - two major intracellular signaling pathways in skeletal muscle15. UPS-mediated 
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catabolism can be measured via the expression of muscle RING-finger protein-1 (MuRF-1) and atrogin-1, two 
muscle-specific E3 ubiquitin ligases, known as atrogenes16.
In contrast, the role of the UPS in primary sarcopenia is less pronounced, with multiple studies demonstrating 
no change or even decreased atrogene activity17–19. Instead, impaired anabolism appears to be the major source 
of muscle loss in primary sarcopenia. Unlike in RC, there is a large body of evidence demonstrating reduced 
testosterone, insulin-like growth factor 1, growth hormone and increased myostatin in age-related muscle loss20.
Myostatin is a negative growth factor primarily released from and acting on skeletal muscle21. The main 
mechanism of myostatin-induced wasting culminates in the suppression of anabolism, with an additional role in 
catabolic stimulation via the UPS22, 23. Myostatin is heavily implicated in primary and a number of secondary sar-
copenic syndromes24. However, the exact role of myostatin and other muscle-derived messengers in RC is unclear.
Janus kinase (JAK)-mediated pathways are important intracellular mediators of muscle atrophy and regener-
ation25. Over 40 cytokines and growth factors signal via JAK-mediated pathways, including IL-626–28. After recep-
tor binding, JAKs become activated, triggering phosphorylation and stimulation of the signal transducer and 
activator of transcription (STAT) pathway29. Activation of various STAT genes has a complex regulatory role in 
muscle growth and repair30 – a topic not previously investigated in the secondary sarcopenia of chronic arthritis.
Adult skeletal muscle retains the ability to respond to injury. However, the anatomical and physiological skel-
etal muscle response following arthritic insult has not been extensively explored. Skeletal muscle regeneration 
occurs via activated satellite cells and is dependent on regulatory transcription factors, principally paired box 7 
(Pax7)31. Other markers of muscle regeneration used to detect myocyte precursors include myogenic differen-
tiation 1 (MyoD), to identify proliferating myoblasts, and myogenic factor 5 (Myf5) and myogenin to recognize 
differentiating myoblasts32.
We aimed to characterize the pattern of muscular injury and response in an animal model of chronic 
inflammatory arthritis. We evaluated alterations to muscle structure as well as the expression of various 
pro-inflammatory, catabolic and regenerative markers.
Results
Weight and CRP. The induction of AiA showed a reduction in rabbit weight in the AiA group compared to 
healthy controls from week 3 until euthanasia (Fig. 1A). Serum CRP was also increased in the AiA group com-
pared to controls at the time of euthanasia (Fig. 1B).
Structural skeletal muscle changes. AiA rabbits had reduced TA weight compared to controls, with 
a seemingly decreased size as demonstrated in posterior macroscopic photographs (Fig. 2A,B). Normalization 
of TA weight according to baseline body weight confirmed an independent significant difference between the 
groups (AiA 0.9 (0.9–1.1) vs. control 1.3 (1.2–1.4), p < 0.05). Measurement of hematoxylin and eosin stained 
sections confirmed gross muscle atrophy with reduced TA CSD and CSA in AiA rabbits compared to controls, as 
shown in Fig. 2C–E.
Histological alterations. Qualitative observation of hematoxylin and eosin cross-sections suggests a het-
erogeneous fiber size and distinct nuclei number in the AiA group in comparison to muscle fibers from controls 
(Fig. 3A). In addition, ATPase staining illustrates a gross reduction in type II fiber size in AiA rabbits (Fig. 3B).
After describing qualitative skeletal muscle changes, we aimed to study whether systemic inflammation would 
lead to greater inflammatory cell infiltrate within skeletal muscle. For that purpose we characterized the pres-
ence of RAM11 positive macrophages. A small population of positive RAM11 cells were present in 60% of TA 
cross-sections from the AiA group. However, macrophages appeared to be localized deep to the epimysium with 
relative endomysial sparing (Fig. 3C). None of the sections from the control group demonstrated RAM11 positive 
cells.
Rhodamine-phalloidin and DAPI staining of EDL revealed distinct shape and a different spatial organization 
of nuclei (Fig. 3D,E) together with a significant increase in myonuclear number in AiA rabbits compared to 
healthy controls (Fig. 3F).
Figure 1. Effect of antigen-induced arthritis on weight and serum C-reactive protein (CRP). (A) Changes in 
body weight in AiA and control rabbits across the study, asterisks (*) denote statistically significant differences 
between AiA and control groups, p < 0.05. (B) Serum CRP levels (µg/ml) at the end of the study. Data represent 
individual values; medians with IQRs are also indicated (n = 8–11 rabbits per group).
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Activation and differentiation markers in muscle regeneration. We then studied whether the 
increased cell number in AiA muscle sections was related to an increase in the satellite cell population. The 
AiA group showed increased Pax7 protein expression in the gastrocnemii of AiA rabbits compared to controls 
(Fig. 4A). This finding is supported by greater immunoreactivity for Pax7 on histological sections (Fig. 4B).
Figure 2. Alterations in skeletal muscle structure. (A) Tibialis Anterior (TA) weight (g). (B) Representative TA 
from healthy control (left) and antigen-induced arthritis (AiA) (right) groups illustrating reduced whole muscle 
size. Posterior view, scale bar = 1 cm. (C) Representative mid-belly cross-sections of TA in control (left) and AiA 
(right) groups stained with Harris haematoxylin and eosin. Scale bar = 2.5 mm. (D) Cross sectional diameter of 
TA (mm). (E) Cross sectional area of TA (mm2). Data represent individual values; medians with IQRs are also 
indicated (n = 8–11 rabbits per group).
Figure 3. Histological alterations in skeletal muscle. (A) Representative sections of tibialis anterior (TA) 
of control (left) and AiA (right) rabbits. Carazzi haematoxylin and eosin staining. Scale bar = 100 μm. (B) 
Representative sections of type I (white) and II (black) fiber distribution and size in TA of control (left) and 
AiA (right) animals stained with ATPase pH 9.4. Scale bar = 100 μm. (C) Representative TA cross-section with 
RAM11 immunostaining of control (left) and AiA (right) groups. Scale bar = 100 μm. Inset showed RAM11 
immunoreactive cell (black arrow) beneath the epimysium in AiA. Scale bar = 25 μm. (D–F) Representative 
focal microscopy images from segments of extensor digitorium longus (EDL) fibers in control (D) and 
AiA rabbits (E). Rhodamine phalloidin (red) was used to stain actin and DAPI (blue) to stain nuclei. Scale 
bar = 30 µm. (F) Myonuclei number in control in comparison to AiA group expressed as number of nuclei per 
100 mm of fiber segment.
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In order to assess the activation and differentiation of myogenic cells in the gastrocnemii of our animals, 
we explored the protein expression of Myf5, MyoD and myogenin. Whereas Myf-5 protein levels remained 
unchanged (Fig. 4C), MyoD and myogenin levels were elevated in the AiA group (Fig. 4D,F). MyoD immunore-
activity confirmed the protein expression results (Fig. 4E).
We also studied the activation of STAT genes to analyze their behavior following catabolic insult. STAT3 phos-
phorylation was significantly reduced in the gastrocnemii of AiA rabbits compared to controls, whereas STAT1 
phosphorylation remained unchanged (Fig. 4G,H).
Pro-inflammatory mediators and atrogenes. Gene expression of IL-1β was increased in the gastrocne-
mii of AiA compared to controls (Fig. 5A). However, expression of IL-6 was equivalent between the two groups 
(Fig. 5B) and both CCL-2 and TNF were significantly reduced in AiA rabbits compared to controls (Fig. 5C,D).
In regards to atrogene expression, there was a significant up-regulation in both atrogin-1 and MuRF-1 in AiA 
rabbits compared to controls (Fig. 5E,F).
In order to investigate whether IL-1β could be responsible for the increase in atrogin-1 and MuRF-1, we 
measured the activity of two downstream intracellular pathways known to stimulate atrogene expression –p38 
MAPK and NF-κB. We found a significant increment in the ratio of phosphorylated p38 MAPK/p38 MAPK in 
AiA animals (Fig. 5G), along with higher levels of active NF-κB able to bind its consensus sequence within the 
nucleus (Fig. 5H).
Figure 4. Activation and differentiation markers in muscle regeneration. Densitometric analysis of Pax7 (A), 
Myf5 (C), MyoD (D), Myogenin (F), pSTAT3 (G) and pSTAT1 (H) protein expression levels in gastrocnemius. 
Data are normalized to endogenous control (α-tubulin) and expressed as arbitrary units (A.U.). Representative 
cropped blots of two animals of each group are shown, control and AiA, respectively. Full length blots are 
presented in Supplementary Figures 1 and 2. Data represent individual values and medians with IQRs are 
also indicated (n = 6 rabbits per group). Representative TA cross sections with Pax7 (B) and MyoD (E) 
immunoreactive nuclei (black arrows) in control (left) and AiA (right) groups. Scale bar = 25 μm. Pax7 = paired 
box protein 7, Myf5 = myogenic factor 5, MyoD = myogenic differentiation 1, pSTAT = phosphorylated signal 
transducer and activator of transcription.
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Local and systemic myostatin levels. Finally, we studied the role of myostatin as an anabolic mediator 
in systemic inflammation. We found a significant reduction in both mRNA and protein expression of myostatin 
from gastrocnemii of AiA rabbits (Fig. 6A,B). Both synovial membrane and serum myostatin expression were 
also reduced in AiA animals when compared to controls (Fig. 6C,D).
Discussion
We have studied the histological alterations of muscle wasting in an animal model of chronic arthritis and the 
derangement of various markers of catabolism and regeneration. We observed an elevated serum CRP together 
with a significant decrease in body weight and muscle size. While RC in humans is widely reported to be associ-
ated with stable weight or weight gain, our results are consistent with previous animal models of inflammatory 
arthritis in rabbits33, rats34, mice35 and monkeys36. Similarly, our findings of reduced muscle CSA, CSD and weight 
is reflected in previous models across a range of species36–38. The loss in muscle size and weight, and the heteroge-
nous myofibre size observed in AiA rabbits may reflect our qualitative observation of preferential wasting of type 
II muscle fibres, an established phenomenon described in experimental arthritis in other species36.
Elevated muscle-derived IL-1β may have contributed to the observed atrophy, structural derangement and 
increased atrogene expression in arthritic rabbits. Receptors for IL-1β have been found on skeletal muscle cells39 
and the administration of IL-1β has been shown to stimulate MuRF-1 and atrogin-1 mRNA expression with sub-
sequent atrophy in vitro15. The modest up-regulation of NF-κB activation and elevated ratio of phosphorylated 
p38 MAPK/p38 MAPK protein in arthritic rabbits may reflect the intracellular effector pathways by which IL-1β 
Figure 5. Pro-inflammatory mediators and atrogenes. Gene expression of control and AiA rabbits normalized 
to endogenous control in gastrocnemius. Data represent individual values and medians with IQRs are also 
indicated (n = 6 rabbits per group, both limbs of each rabbit are represented) for IL-1β (A), IL-6 (B), CCL-2 
(C), TNF (D), atrogin-1 (E) and MuRF1 (F). (G) Protein expression of p38 MAPK. Data are expressed as 
arbitrary densitometric units (A.U.) and normalized relative to the expression of phosphorylated p38 MAPK. 
Representative cropped blot of two animals of each group are shown, control and AiA, respectively. Full-length 
blot is presented in Supplementary Figure 2. (H) Active protein levels of NF-κB measured by enzyme linked 
immunoabsorbant assay. Graphs show individual values and medians with IQRs are also indicated (n = 6 
rabbits per group). IL = interleukin, CCL-2 = C-C Motif Chemokine Ligand 2, TNF = tumor necrosis factor, 
MuRF1 = muscle RING-finger protein-1.
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contributes to proteolysis. IL-1β has been shown to stimulate NF-κB and p38 MAPK signaling with subsequent 
atrogene induction and myotube atrophy in vitro15, 40, 41. Therefore, we suggest that the increased atrogin-1 and 
MuRF-1 expression as well as a proportion of the sarcopenia observed in AiA rabbits may have been driven by 
direct autocrine IL-1β signaling.
According to our data, animals with AiA displayed signs of simultaneous muscle wasting and repair. The 
myonuclear expansion observed in arthritic rabbits is an anatomical marker of muscle growth and regeneration42. 
Indeed, myonuclei number has been shown to increase after sarcopenic challenge in rats43. Increased Pax7 pro-
tein expression alongside greater Pax7 immunoreactivity in AiA rabbits suggests that satellite cell proliferation is 
responsible for a proportion of the increased myonuclear mass. In the presence of myogenic regulatory factors, 
Pax7-expressing satellite cells have the ability to self-renew, differentiate and fuse in order to repair injured skel-
etal muscle44. In line with experimental arthritis in other species13, 45, our model of AiA demonstrated elevated 
MyoD and myogenin, although contradictory results have been published34. Increased MyoD enables satellite cell 
proliferation and up-regulation of myogenin thereby facilitating myoblast differentiation and muscle regenera-
tion32, 46. Our finding of equivalent Myf5 protein expression between groups may reflect the non-obligatory and 
transient expression of Myf5 in adult myogenesis47.
We propose that the reduced myostatin and pSTAT3 expression from AiA rabbits may contribute to the 
observed myonuclear expansion and increased Pax730, 48. In addition to promoting cellular and particularly satel-
lite cell expansion, the decreased pSTAT3 expression in the AiA group may have ameliorated UPS-mediated pro-
teolysis. While IL-6 mRNA was equivalent in both groups, decreased expression of its downstream intracellular 
effector may decrease atrogin-1 expression and down-regulate the acute phase response, thereby addressing the 
proportion of sarcopenia that is driven by inflammation25, 49.
Perhaps the most striking marker of anabolic compensation in our model is reduced myostatin expression 
across multiple sites. Myostatin negatively regulates multiple aspects of skeletal muscle homeostasis, primarily via 
decreased myogenesis22, 23, 50. Despite involvement in the muscular wasting associated with cancer51, congestive 
heart failure52 and chronic obstructive pulmonary disease53, a role for myostatin in RC has not been consistently 
demonstrated. While Dankbar et al. recently demonstrated elevated myostatin expression in synovial membranes 
of patients with RA, it is not known whether these patients were also affected by RC54. Furthermore, of the seven 
previous models of inflammatory arthritis that we found in the literature, only three reported increased myostatin 
mRNA or protein36, 45, 54. A number of the conflicting reports may originate from myostatin mRNA-protein dis-
cordance. However, concordance between myostatin mRNA and protein expression from skeletal muscle in our 
model suggests a true reduction in myostatin secretion.
Figure 6. Local and systemic myostatin levels in skeletal muscle, synovium and serum. (A) Myostatin gene 
expression in gastrocnemius from control and AiA rabbits (n = 6 rabbits per group, both limbs of each rabbit are 
represented). (B) Myostatin protein expression in gastrocnemius from control and AiA rabbits. Data for protein 
expression are expressed as arbitrary densitometric units (A.U.) and normalized relative to the expression 
of α-tubulin (n = 6 rabbits per group). Representative cropped blot of two animals of each group are shown, 
control and AiA, respectively. Full length blot is presented in Supplementary Figure 1. (C) Myostatin gene 
expression in the synovium. (D) Serum myostatin levels in control and AiA rabbits. MSTN = Myostatin. Graphs 
show individual values and medians with IQRs are also indicated (n = 8–11 rabbits per group).
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An alternative explanation for our results may be found in our methodology - including variance in spe-
cies, method of arthritis induction and the model duration. Ramirez et al. found a 4.3-fold increase in myosta-
tin mRNA at two days, which decreased to a 2-fold increase at seven days and then returned to baseline 15 
days post-arthritis induction45. These data may suggest a role for myostatin in early RC-induced sarcopenia that 
diminishes over a prolonged period. We propose that the extended duration of our model may enable a com-
pensatory down-regulation of myostatin with a subsequent anabolic stimulus. Such myostatin suppression has 
been observed in regenerating muscles in mice models of muscular dystrophy55. Furthermore, a recent study of 
postoperative patients found significantly reduced serum myostatin at two postoperative time points, with the 
lowest myostatin levels coinciding with the highest serum CRP56. The relationship between inflammatory atrophy 
and compensatory myostatin inhibition requires further investigation to determine its merit and the mechanism 
of down-regulation.
Finally, we found a reduction in TNF mRNA expression in arthritic animals. While induction of the UPS 
after exposure to exogenous TNF has been previously demonstrated57, this observation is not universal58, 59. In 
addition, despite previous animal models demonstrating increased TNF expression in RC13, 37, its role in humans 
is less conclusive. Previous studies of anti-TNF agents in RA patients have failed to show significant improve-
ments in fat-free mass60–63. Further research is clearly indicated to determine the exact role of TNF in the sar-
copenia of inflammatory arthritis. In a similar pattern to TNF, CCL-2 was also reduced in AiA rabbits. CCL-2 
and subsequent macrophage attraction in acute inflammation is thought to be critical for future muscle repair64. 
However, the decreased CCL-2 expression seen in the arthritis group may be a reflection of the chronicity of our 
model. Indeed, the finding of sub-epimysial RAM11 positive cells may indicate prior CCL-2-driven macrophage 
infiltration.
A limitation of our study is the lack of a precise distinction between the effect of arthritis-induced systemic 
inflammation from that of pain-induced inactivity. Whereas disuse atrophy is a relatively uncomplicated form of 
muscle loss, mostly dependent on the loss of a mechanical input, in inflammatory disease states such as cancer, 
HIV/AIDS, sepsis and rheumatoid arthritis, there is also a meaningful involvement of a complex pro-catabolic, 
hormonal and cytokine environment to contemplate. In these conditions, systemic inflammation is often asso-
ciated with asthenia, anorexia and inactivity due to pain2. Each factor contributes to the overall atrophy via a 
complex interplay between the various pathways of muscle loss. Therefore, even when employing controlled 
experimental models, it is difficult to isolate the specific contribution of each component. It is very likely that an 
undetermined contribution of inactivity due to pain and discomfort may exist in the muscle alterations described 
in this study, as it happens in RA patients65. Although previous experimental models of muscle disuse atrophy 
showed increased atrogene expression with an associated transient increase in local inflammatory response, 
arthritis does appear to cause an independent and distinct pattern of muscle wasting in the direct comparison 
trials of disuse and arthritic atrophy16, 34, 45. Furthermore, our data suggest a systemic sarcopenic effect as showed 
by the similar extent of lower limb muscles and total body weight loss in AiA.
Our study has confirmed the muscular atrophy of RC in a new species. After investigating different patho-
genic processes, we suggest that chronic arthritis alters the precise homeostatic equilibrium of skeletal muscle 
remodeling. The systemic proinflammatory milieu and local elevated IL-1β may activate two major intracellular 
pathways of proteolysis. In addition, we have presented anatomical, mRNA and protein markers of compensatory 
anabolic activity. Myonuclear expansion, down-regulation of myostatin signaling, increased MyoD and myogenin 
and decreased pSTAT3 signaling may all reflect attempts to repair the catabolic insult of inflammatory arthritis. 
Subsequent research is required to evaluate these hypotheses and convert them into muscle-specific therapies that 
may allow maintenance of skeletal muscle mass in patients suffering from RC.
Methods
Experimental model in rabbits. Adult, male New Zealand rabbits with a body weight of 3 to 3.5 kg (Granja 
San Bernardo, Navarra, Spain) were used for the experiment. Animal handling and experimentation were per-
formed in accordance with Spanish Regulations and the Guidelines for the Care and Use of Laboratory Animals 
drawn up by the National Institutes of Health (Bethesda, MD, USA). The experimental protocol was approved by 
the Institutional Ethics and Welfare Committee of the Institute and Health Research Jiménez Díaz Foundation.
After two weeks of adaptation to our facilities, 20 rabbits were randomly assigned into two groups – 
antigen-induced arthritis (AIA) and control. Arthritis was induced according to a previously described proto-
col66. Briefly, animals were given two intradermal injections of 1 ml ovalbumin (OVA) (4 mg/ml; Sigma-Aldrich, 
St. Louis, MO, USA) in Freund’s complete adjuvant (Difco, Detroit, MI, USA). Five days after the second injec-
tion, 1 ml of OVA (5 mg/ml in 0.9% NaCl) was injected intra-articularly into the knee joints on a weekly basis over 
the following four weeks. One AIA animal died of unknown cause and the remaining rabbits completed the study 
(n = 11). Control rabbits underwent no experimental intervention (n = 8).
Tissue collection. At the end of the study, rabbits were bled from their marginal ear vein, and then eutha-
nized with an overdose of intra-cardiac sodium thiopental (50 mg/kg; Tiobarbital, Braun Medical SA, Barcelona, 
Spain). The left lower limb was shaved and an anterior skin incision was made from patella to mid-paw to dissect 
tibialis anterior (TA) and extensor digitorum longus (EDL). Proximal gastrocnemius and synovia from both 
limbs were also collected in six animals from each group for gene and protein expression studies, snap frozen in 
liquid nitrogen and stored at −80 °C.
Post-dissection, TA was immediately transferred to a cell plate for anterior and posterior photographs. A 1mm 
segment of the TA mid-belly, defined as the widest identifiable region, was sectioned, dehydrated in talc powder 
and placed cross-sectionally in a template of Optimal Cutting Temperature compound (OCT; Fisher Scientific, 
USA). Each OCT embedded cross-section was then set in liquid nitrogen before storage at −80 °C for sectioning, 
www.nature.com/scientificreports/
8ScIEnTIfIc RePoRts | 7: 6311 | DOI:10.1038/s41598-017-06581-6
staining and measurement. The distal portion of the remaining TA was fixed in formaldehyde 4% and then paraf-
fin embedded for detection of RAM11, Pax7 and MyoD immunoreactivity.
EDL muscles were transferred to 0.2% collagenase type I (Sigma-Aldrich, St Louis, Mo, USA) in Dulbecco’s 
modified eagle’s medium (DMEM, Lonza, Basel, Switzerland), 4.5 g/L glucose, 1% L-glutamine with 110 mg/ml 
sodium pyruvate, and incubated at 37 °C for 1 hour. Under a stereoscopic microscope, EDL muscle was flushed in 
warm medium until fibers were released, as previously described67.
Serum biochemical markers. Ten milliliters of blood were used for serum extraction. Specific 
enzyme-linked immunosorbent assay kits were used to measure CRP (Abcam, ab157726, Cambridge, UK) and 
myostatin (Cloud Clone Corp., CEB653, Houston, TX, USA).
Histological studies. Frozen TA muscles were sectioned at −30 °C in consecutive 5 μm slices with a Leica 
CM1850 cryostat (Leica Co., Germany). Two consecutive sections were oriented in the same plane then attached 
to a single microscope slide (Superfrost PLUS; Thermo Scientific, USA).
Hematoxylin and eosin stained TA cross-sections were photographed using an automated iScan Coreo slide 
scanner (Ventana Medical Systems, USA) with a maximum objective of 20x. The cross-sectional diameter (CSD) 
and cross-sectional area (CSA) were measured using the Image Viewer software package (Ventana Medical 
Systems, USA). CSD was measured using the Feret’s diameter, defined as the maximum diameter across the lesser 
aspect of the section. Parallel horizontal lines at the top and bottom of the image ensured consistent perpendic-
ular measurements. CSA was calculated automatically after tracing the outline of the cross-section. All measure-
ments were taken manually by two observers blinded to each group.
ATPase staining was performed in TA cross-sections. Briefly, cross-sections were incubated 45 minutes in 
0.1 M glycine/NaCl buffer adjusted to pH 9,4 with 0,75 M CaCl2 and 5 mg ATP (Sigma-Aldrich, St Louis, Mo, 
USA), rinsed in distilled water and afterwards incubated in 2% cobalt chloride, then immersed in dilute (1/10) 
ammonium chloride to develop type 1 (white) and type 2 fiber (black) delineation, and finally dehydrated in 
ascending alcohol series and mounted with di-n-butylphthalate in xylene (DPX, mounting medium, VWR 
International Ltd., Lutterworth, UK).
Immunohistochemistry. Paraffin embedded TA was sectioned at a width of 2 microns. Macrophages were 
visualized using mouse monoclonal RAM11 primary antibody (36.2 mg/L at a 1/100 dilution; Dako, M0633, 
Golstrup, Denmark), satellite cells were immunoreactive to Pax 7 (28 μg/ml; Developmental Studies Hybridoma 
Bank, AB 528428, Iowa City, IA, USA) and MyoD (13.5 μg/ml; Dako, M3512, Carpinteria, CA, USA). 10 mM 
citrate buffer was used for antigen retrieval (pH 6, 30 minutes at 85 °C). Primary antibodies were detected with 
sheep anti-mouse (Amersham, RPN1001, Arlington Heights, IL, USA) and anti-goat (Merck Millipore, AB324P, 
Darmstadt, Germany) IgG secondary antibodies at 1/100 and 1/250 dilution and visualized with a horserad-
ish peroxidase/ABC complex using 3,3 diaminobenzidine tetra-hydrochloride as the chromogen (Dako, 
K3468, Golstrup, Denmark). Sections were counterstained with hematoxylin and mounted with DPX medium. 
Photographs were obtained using a Leica DMD108 digital micro-imaging instrument (Leica, Microsystems, Inc. 
Buffalo Grove, IL, USA) at 10x and 40x magnification.
Fluorescent labeling of EDL fibers. Ten fiber segments from each animal were collected in a plate covered 
with matrigel (Corning, NY, USA) forming two different pools, AiA and control. From each pool, fiber segments 
were transferred to a chamber slide and fixed in 4% formaldehyde, then rinsed and incubated in 0.5% Triton to 
allow permeabilization. Fibers were incubated in the dark in 100 nM rhodamin-phalloidin (Cytoskeleton, Denver, 
CO, USA) over 45 minutes. DAPI (1 μg/ml, Invitrogen, Eugene, OR, USA) was used to counterstain nuclei dur-
ing 30 minutes at room temperature. Finally, slides were mounted in Fluorsave (Calbiochem, Merck Millipore, 
Darmstadt, Germany) and visualized through Leica TCS SP2 instrument (Leica, Microsystems, Inc., Buffalo 
Grove, IL, USA). Nuclei count was performed using LAS AF software (Leica, Microsystems, Inc. Buffalo Grove, 
IL, USA) and expressed as number of nuclei per 100 μm of segment fiber.
Gene expression. Total RNA was isolated from gastrocnemius and synovium using TriPure isolation rea-
gent (Roche Diagnostics, Indianapolis, IN, USA), according to the manufacturer’s instructions. A total of 1 µg 
RNA was reverse-transcribed with a high capacity cDNA kit (Applied Biosystems, San Francisco, CA, USA) 
and RNA expression was quantified by single-reporter real time PCR using the StepOnePlus™ detection sys-
tem and StepOne™ software v2.2 (Applied Biosystems, San Francisco, CA, USA). TaqMan® primers and 
probes were used to measure IL-6 (Oc04097053_m1), TNF (Oc03397715_m1), myostatin (Oc03399520_m1), 
IL-1 (Oc03823250_s1) and CCL-2 (Oc03823583_s1). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; 
Oc03823402_g1) was used as an endogenous control. SYBR Green® primers were designed using Primer3Plus 
and Primer-BLAST software from sequences obtained from GenBank (NIH, USA) and used to measure MuRF-1 
(XM_008265917.1; Fw: CACCTTCCTCATGAGTGCCA, Rv: TCTGTCCCAAAGTCGATGGC), atrogin-1 
(XM_002710762.2; Fw: TACTGCACTTTGGGGGAAGC, Rv: ATCAGTTCCAACAGCCGGAC) and the endog-
enous control, peptidylprolyl isomerase A (PPIA, NM_001082057.1; Fw: AGGGTTTATGTGCCAGGGTG, Rv: 
AAGATGVCCAGGACCTGTGTG). All target genes were normalized relative to the expression of the endoge-
nous controls.
Preparation of total and nuclear extracts from tissue. Frozen gastrocnemius was crushed using a 
mortar and a pestle cooled with liquid nitrogen. For the extraction of total protein, 50 mg of pulverized tissue was 
homogenized in a buffer containing 15 mM HEPES, 10% glycerol, 0.5% NP-40, 250 mM NaCl, 1 mM EDTA, 1 mM 
phenylmethanesulfonylfluoride (PMSF) and a phosphatase- and protease-inhibitor cocktail (Sigma-Aldrich, St. 
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Louis, Mo, USA). Extracts were incubated 15 minutes on ice and centrifuged 15 minutes at 12 000 rpm and 4 °C. 
Supernatants were collected and protein concentration was determined by the BCA method.
For the preparation of nuclear extracts, 50 mg of pulverized frozen tissue was homogenized with a Dounce tis-
sue grinder in a hypotonic buffer containing 20 mM HEPES, 5 nM NaF, 10 μM Na2MoO4, 0.1 mM EDTA, 0.01% 
NP-40, 1 M dithiotreitol (DTT) and a phosphatase- and protease-inhibitor cocktail (Sigma-Aldrich, St. Louis, Mo, 
USA). Extracts were centrifuged 10 minutes at 850 g and 4 °C. Cell pellets were gently re-suspended in hypotonic 
buffer, incubated 15 minutes on ice and centrifuged 30 seconds at 14 000 rpm and 4 °C. Nuclear pellets were then 
re-suspended in 50 μl of Complete Lysis Buffer (Active Motif, La Hulpe, Belgium), incubated 30 minutes on ice in 
a rocking platform and centrifuged 10 minutes at 14 000 rpm and 4 °C. Supernatants were collected and protein 
concentration was determined by the Bradford method.
Western Blot. 20 μg of total protein was resolved on 12% or 15% acrylamide - SDS gels and transferred to a 
nitrocellulose membrane in 48 mM Tris, 39 mM glycine and 20% methanol buffer at 25 V for 30 minutes at room 
temperature. Membranes were blocked in 5% skimmed milk in TBS Tween® 1 hour at room temperature and 
incubated overnight at 4 °C using anti-myostatin/GDF8 antibody (0.002 mg/ml at a 1/500 dilution; R&D Systems, 
AF788, Minneapolis, MN, USA), phospho-STAT3 (0.5 mg/ml at a 1/200 dilution; R&D Systems, MAB4607, 
Minneapolis, MN, USA), phospho-STAT1 (0.5 mg/ml at a 1/100 dilution; Affymetrix eBioscience, 14-9008, 
SanDiego, CA, USA) Pax7 (28 ug/ml, at 1/10 dilution, Developmental Studies Hybridoma Bank, AB 528428, Iowa 
City, IA, USA), p38 MAPK (1 mg/ml at a 1/1000 dilution; Millipore, ABS29, Temecula, CA, USA), phospho-p38 
MAPK (1 mg/ml at a 1/1000 dilution; Abcam, ab45381, Cambridge, UK), Myogenin (1 mg/ml at a 1/500 dilu-
tion; Abcam, ab82843, Cambridge, UK) and MyoD (1 mg/ml at a 1/1000 dilution; Abcam, ab16148, Cambridge, 
UK). Antibody binding was detected by enhanced chemoluminescence using peroxidase-labeled anti-goat 
(Merck Millipore, Darmstadt, Germany), anti-rat (Thermo Scientific, Waltham, MA, USA) and anti-mouse (GE 
Healthcare LifeSciences Piscataway, NJ, USA) secondary antibodies at a 1/5000, 1/20000 and 1/5000 dilution, 
respectively. Expression levels of loading control were validated with anti-α-tubulin (Sigma-Aldrich, St Louis, 
Mo, USA) at 1/8000 dilution. Results were expressed as arbitrary densitometric units (A.U.) and normalized 
relative to the expression of α-tubulin.
Measurement of NF-κB activation by enzyme linked immunosorbent assay (ELISA). 5 μg 
of nuclear protein were analyzed with the TransAM NF-κB p65 ELISA kit (#40096, Active Motif, La Hulpe, 
Belgium), according to the manufacturer’s instructions. Absorbance was measured at 450 nm and the relative 
amount of p65 NF-κB protein between control and AiA rabbits was calculated.
Statistical analysis. All statistical analyses were performed using SPSS version 21.0 software for Windows 
(IBM, New York, NY, USA). Descriptive data are expressed as the median ± interquartile range (IQR). 
Comparisons between multiple groups used Kruskal-Wallis tests with Bonferroni correction of post hoc Mann–
Whitney U tests, p < 0.05 was considered significant.
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